비보존 제약

082800KOSDAQ

49.7 / 100

Reference Date: 2026-09-08

Financial Score12.5 / 40

News Sentiment20.2 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 12.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Bibozen Pharmaceuticals is a specialized pharmaceutical company primarily engaged in the manufacturing and sales of prescription and over-the-counter drugs, offering a wide range of products including cardiovascular medications, diabetes treatments, and analgesics. The company operates over 190 product items through diverse business activities such as CMO, OEM, and international exports, while focusing on the research and development of innovative new drugs.

Number of Employees

292people

Average Salary

52.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.65Industry Average 1.200.0Point

2.2x industry avg (risky)

ROE

-36.21Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

20.79Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼380.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -16.3% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 7Neutral 1Negative 0Average Sentiment Score 80.6

Positive
비보존제약 '어나프라주', 韓거점병원·美임상 투트랙 공략
비보존제약의 비마약성 진통제 '어나프라주'가 국내 주요 병원을 통해 매출 성장을 이어가며 긍정적인 시장 반응을 얻고 있다.
Positive
비보존제약, 中 기업과 '어나프라주' 완제품 공급 계약
비보존제약의 중국 진출 계약으로 인해 어나프라주의 시장 확대 기대.
Neutral
[바이오스냅] 의료용 마약류 투약 확인 대상에 프로포폴 추가
추가적인 프로포폴 투약 확인 대상 지정은 관련 제약 회사들의 협력 강화를 보여주나, 비보존 제약의 직접적인 영향은 제한적이다.

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 3,175Won52-week high 7,74552-week low 2,155

1-month return5.0Point

1m +12.79% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-21
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-19
Neutral반기보고서 (2026.06)2026-08-14
Neutral[기재정정]사업보고서 (2025.12)2026-08-12